

CELGENE CORP /DE/  
Form 8-K  
February 20, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 20, 2015

**CELGENE CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware                                      001-34912                                      22-2711928  
(State or other jurisdiction of      (Commission File Number) (IRS Employer Identification No.)  
incorporation)

86 Morris Avenue, Summit, New Jersey 07901  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (908) 673-9000

Edgar Filing: CELGENE CORP /DE/ - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 OTHER EVENTS**

On February 20, 2015, Celgene Corporation announced that the European Commission has approved REVLIMID® (Lenalidomide) for the treatment of adult patients with previously untreated multiple myeloma (MM) who are not eligible for transplant.

Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcement.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit 99.1 – Press Release dated February 20, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: February 20, 2015 By: /s/ Peter N. Kellogg  
Peter N. Kellogg  
Executive Vice President  
Chief Financial Officer  
(principal financial and accounting officer)

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Press Release dated February 20, 2015.